The content on this site is intended for healthcare professionals only
Dr Stephen Chan speaks to ecancer about the phase 3 keynote-937 study.
In this trial, adjuvant pembrolizumab did not improve recurrence-free survival compared with placebo in patients with hepatocellular carcinoma who achieved complete response after surgical resection or local ablation.
At a median follow-up of more than four years, recurrence-free survival and overall survival were similar between treatment arms, and the primary endpoint was not met, precluding further overall survival analysis.
While pembrolizumab was associated with higher rates of grade ≥3 adverse events, no new safety signals or treatment-related deaths were observed.
These results indicate that pembrolizumab does not provide clinical benefit as adjuvant therapy following curative-intent treatment in HCC.
Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer
Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer
Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors
Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer
MS-553 shows promise in treating chronic lymphocytic leukaemia
TKI chemotherapy and ponatinib improve survival outcomes in blast phase CML
Consolidation treatment delays do not compromise survival in MRD-negative adult ALL
Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer
Black patients show inferior survival despite similar cytogenetics and treatment response
